Ulrike Kriemler‐Krahn

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with <b>β</b>‐thalassaemia: the ESCALATOR study

Alì Taher, Amal El‐Beshlawy, Mohsen Saleh Elalfy et al. · European Journal Of Haematology · 2009 · 145 citations · Full text

Medicine, Hematology, Pharmacology +17

Multicenter validation of spin‐density projection‐assisted R2‐MRI for the noninvasive measurement of liver iron concentration

Timothy G. St. Pierre, Amal El‐Beshlawy, Mohsen Saleh Elalfy et al. · Magnetic Resonance in Medicine · 2013 · 123 citations

Medicine, Hematology, Radiology +17

Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with <b>β</b>‐thalassaemia

Shahina Daar, Anil Pathare, Hanspeter Nick et al. · European Journal Of Haematology · 2008 · 75 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Improved Treatment Satisfaction and Convenience with Deferasirox in Iron-Overloaded Patients with β-Thalassemia: Results from the ESCALATOR Trial

Alì Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy et al. · Acta Haematologica · 2010 · 46 citations

Medicine, Pharmacology, Pharmacotherapy +17

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7‐yr follow‐up from the ESCALATOR study in patients with β‐thalassaemia

Alì Taher, Mohsen Saleh Elalfy, Kusai Al Zir et al. · European Journal Of Haematology · 2011 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17